Oligodendroglioma Clinical Trial
Official title:
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
Rationale: Standard postoperative treatment of isocitrate dehydrogenase 1/2 mutated grade 2
and 3 glioma (IDHmG) consists of radiotherapy and chemotherapy. The improving prognosis of
these patients leads towards more emphasis on the long-term effects of treatment.
Specifically radiotherapy has been implicated in the development of delayed neurocognitive
deterioration. The impact of modern radiotherapy techniques (such as intensity modulated
radiotherapy, volumetric modulated radiotherapy and proton beam therapy) and chemotherapy on
general toxicity, late neurocognitive outcomes and imaging changes is currently unclear.
Objectives:
- To report treatment outcomes and radiation-induced toxicity from a prospective,
multicentre observational cohort of IDHmG patients treated with radiotherapy and
chemotherapy,
- To integrate radiotherapeutic dose distributions, imaging changes and neuropsychological
outcome in IDHmG.
- To evaluate the Dutch selection criteria for proton therapy applied to IDHmG based on
the outcomes collected in this observational study.
- To assess the impact of proton and photon therapy on health-related quality of life
(HRQoL) and health-related economics (HR-E) in IDHmG patients.
- To collect genetic material for future translational research into the interaction
between germline DNA, prognosis and radiation-induced toxicity.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: This project is a multicentre, observational cohort of patients undergoing
radiotherapy and chemotherapy for IDHmG. The protocol closely follows the local guidelines
for clinical follow-up. Specific to the study are extra questionnaires and specific imaging
acquired during scheduled MRI's. Routine neuropsychological investigation is standard of care
in Erasmus Medical Center (Erasmus MC), but not in all participating centers. We feel the
additional burden of participation in this study to be low.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Recruiting |
NCT04843085 -
Proteomic Characterization of Aggressive Oligodendrogliomas
|
||
Completed |
NCT02903784 -
Neural Basis of Language Processing
|
N/A | |
Completed |
NCT00165360 -
Prolonged Daily Temozolomide for Low-Grade Glioma
|
Phase 2 | |
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Completed |
NCT02530320 -
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
|
Phase 2 | |
Terminated |
NCT00389090 -
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02549833 -
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
|
Phase 1 | |
Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
Recruiting |
NCT05624736 -
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
|
||
Recruiting |
NCT05345002 -
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
|
Phase 2 | |
Completed |
NCT03900689 -
Social Determinants of Health in Glioblastoma Population
|
||
Completed |
NCT02747407 -
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
|
||
Recruiting |
NCT04970615 -
Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Terminated |
NCT01836549 -
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
|
Phase 2 | |
Recruiting |
NCT03796273 -
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
|
Early Phase 1 | |
Terminated |
NCT00031538 -
Genetic Analysis of Brain Tumors
|
||
Completed |
NCT01609790 -
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05513859 -
Investigational Imaging Technique During Brain Surgery
|
N/A |